You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel multi-sensing seat cover system for prevention of sitting-related pressure injuries in individuals with Alzheimer's disease or related dementias
SBC: Adapt Design Works, LLC Topic: NIAABSTRACT The long-term objective of this project is to create a sensor-based monitoring technology for use by caregivers, clinicians, and individuals living with Alzheimer’s disease or Alzheimer’s disease related dementia (AD/ADRD) to mitigate the risk of pressure injuries related to prolonged sitting. Pressure injury prevalence is disproportionately high in the aging AD/ADRD population due to ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Microbial Synthesis of Therapeutic Bile Acids for Alzheimer's Disease
SBC: Metselex, Incorporated Topic: 105ABSTRACT This Phase STTR Phase II proposal aims to engineer and scale-up a synthetic metabolic pathway in a microbial host to produce UDCA and related compounds. Additionally, the UDCA produced from the engineered synthetic metabolic pathway will be used to synthesize derivatives for testing in our Alzheimer’s Disease cell and animal models. The proposed work has high intellectual merit for the ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a treatment for durable remission of HIV using transposon engineered CAR-T and NK cells
SBC: MARPAM PHARMA LLC Topic: NIAIDProject Summary MarPam Pharma aims to develop a one-time treatment for achieving durable remission of human immunodeficiency virus (HIV), after which patients will no longer need to take antiretroviral therapy. Our treatment is an autologous HIV-specific chimeric antigen receptor (CAR) immune cell therapy that employs the CXCR5 chemokine receptor as a homing device to direct either anti-HIV T cell ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Two-for-one Stroke Thrombectomy:A novel Dual DAC to enhance navigability, lumen size, aspiration efficiency, and persistent flow arrest in mechanical thrombectomy
SBC: PIRAEUS MEDICAL, INC. Topic: 105PROJECT SUMMARY/ABSTRACT The long-term goal of this proposal is to improve the care of patients suffering from Large Vessel Occlusion Acute Ischemic stroke. Currently, mechanical thrombectomy techniques can achieve revascularization in over 70% of cases, and physicians are rapidly adoption aspiration thrombectomy over stent-trievers. Aspiration maintains equivalent angiographic and clinical outcom ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Advanced Quantitative Magnetic Resonance Imaging Phantoms for Nonalcoholic Fatty Liver Disease
SBC: CALIMETRIX LLC Topic: NIBIBPROJECT SUMMARYThe overall goal of this Phase I proposal is to design and test the feasibility of novel magnetic resonance imaging (MRI) reference standards (“phantoms”) that are urgently needed for comprehensive and standardized quality assurance (QA) of quantitative MRI biomarkers of non-alcoholic fatty liver disease (NAFLD). We propose to develop 1) a quantitative MR elastography (MRE) stif ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
GENOMICE (Game Exploring Nuances in Offspring to Master Interactions of Chromosome Expression)
SBC: SMART INFORMATION FLOW TECHNOLOGIES LLC Topic: NHGRIPROJECT SUMMARY Genomics has become an essential element of biomedical science, playing multiple roles in rapidly addressing the COVID-19 pandemic, understanding medical complications to develop more effective preventative care and treatments, and modeling diseases in laboratory specimens for study. Despite the increasing relevance of genomics to people's everyday lives, genomics literacy in the U ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Virtual Reality Technologies for Dynamic Balance Rehabilitation in People with Stroke
SBC: KOBUK TECHNOLOGIES LLC Topic: NICHDPROJECT SUMMARY/ABSTRACT This project aims to quantify and establish elements of immersive virtual reality (VR) software that, when paired with treadmill training, produce balance perturbations that can be scaled to improve dynamic balance and are tolerated by people with stroke. VR continues to be used as an interactive and engaging way for clinicians to interact with patients during physical the ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Framework for mHealth App Security and Privacy Analysis
SBC: UBITRIX INTERNATIONAL, INC. Topic: NLMPROJECT SUMMARY/ABSTRACT With the increased use of mobile health (mHealth) apps to improve health outcomes, protecting private health data is becoming increasingly important. These mHealth apps are offered by healthcare providers and used by patients for various reasons such as paying bills, scheduling appointments, sending messages to providers, accessing lab results, and viewing prescriptions an ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Neural organoid models of the immunological microenvironment of glioblastoma for drug discovery applications
SBC: STEM PHARM, INCORPORATED Topic: 102Project Summary/Abstract Glioblastoma (GBM) is the most prevalent primary brain tumor in adults with extremely poor survival rates and largely unchanged standard of care. While there are many challenges to developing better GBM treatments, one of the major challenges is the immune-suppressive environment commonly found within GBM tumors. This immune-suppressive nature results in a tumor that is no ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Prodrugs of potent and selective protease inhibitors as tauopathy therapeutics
SBC: MYRIEL, INC. Topic: 105PROJECT ABSTRACT Myriel, Inc., is a pharmaceutical start-up company founded in 2022 to find cures for tauopathies, including Alzheimer’s disease and related dementias (ADRD), which impair cognition in 32% of US adults 65 years and older. The goal of this Phase 1 STTR application is to provide Myriel with a brain-penetrant analogue of our lead compound, GPHR ‘739, the first potent, selective, r ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health